Search results
Results from the WOW.Com Content Network
It is an uncommon form of endometrial cancer that typically arises in postmenopausal women. It is typically diagnosed on endometrial biopsy, prompted by post-menopausal bleeding. Unlike the more common low-grade endometrioid endometrial adenocarcinoma, uterine serous carcinoma does not develop from endometrial hyperplasia and is not hormone ...
Papillary and follicular carcinoma; M8341/3 Papillary microcarcinoma (C73.9) M8342/3 Papillary carcinoma, oxyphilic cell (C73.9) M8343/3 Papillary carcinoma, encapsulated (C73.9) M8344/3 Papillary carcinoma, columnar cell (C73.9) Papillary carcinoma, tall cell; M8345/3 Medullary carcinoma with amyloid stroma (C73.9) Parafollicular cell carcinoma
A. Low-magnification view shows a focal high-grade serous carcinoma developing from the papillae (square) in a background of a typical serous borderline tumor. B. Higher magnification demonstrates enlarged and atypical high-grade serous carcinoma cells that organize in a papillary architecture.
Endometrial carcinomas originate from cells in the glands of the endometrium (uterine lining). These include the common and readily treatable well-differentiated endometrioid adenocarcinoma, as well as the more aggressive uterine papillary serous carcinoma and uterine clear-cell carcinoma.
Carcinosarcoma of the uterus. In gross appearance, MMMTs are fleshier than adenocarcinomas, may be bulky and polypoid, and sometimes protrude through the cervical os.On histology, the tumors consist of adenocarcinoma (endometrioid, serous or clear cell) mixed with the malignant mesenchymal elements; alternatively, the tumor may contain two distinct and separate epithelial and mesenchymal ...
Serous carcinoma is a Type II endometrial tumor that makes up 5–10% of diagnosed endometrial cancer and is common in postmenopausal women with atrophied endometrium and black women. Serous endometrial carcinoma is aggressive and often invades the myometrium and metastasizes within the peritoneum (seen as omental caking ) or the lymphatic system.
A mutation in BRCA1 or BRCA2 can confer a lifetime ovarian cancer risk of 40-50% and 10-20% respectively, [15] with BRCA2 mutations strongly associated with better clinical outcomes. A specific tumour protein 53 ( TP53 ) expression pattern in the Fallopian tube epithelium – the ‘p53 signature’ - is thought to be a precursor marker of HGSC.
Uterine clear-cell carcinoma (CC) is a rare form of endometrial cancer with distinct morphological features on pathology; it is aggressive and has high recurrence rate. Like uterine papillary serous carcinoma CC does not develop from endometrial hyperplasia and is not hormone sensitive, rather it arises from an atrophic endometrium.